Upon stratifying patients with glioma into four groups based on both NDUFA6-DT expression and TMB, we observed that in LGG, those with high NDUFA6-DT expression and low TMB exhibited the most significant survival advantage (Figure 4e). This evidence concerns the gene NDUFA6 and glioma.